Raised maternal serum placenta growth factor concentration during the second trimester is associated with Down syndrome

@article{Su2002RaisedMS,
  title={Raised maternal serum placenta growth factor concentration during the second trimester is associated with Down syndrome},
  author={Y. N. Su and Jenn-Jein Hsu and C. N. Lee and W F Cheng and C C Kung and F J Hsieh},
  journal={Prenatal Diagnosis},
  year={2002},
  volume={22}
}
To compare early second‐trimester maternal serum placenta growth factor concentrations in Down syndrome pregnancies and those in normal pregnancies. 
Early first‐trimester maternal serum placental growth factor in trisomy 21 pregnancies
TLDR
To measure maternal serum placental growth factor (PlGF) levels in trisomy 21 cases and controls in samples drawn before 11 weeks' gestation, data are analyzed to establish a baseline level for PlGF levels and establish an apples-to- apples relationship between case and controls.
Maternal serum placental growth factor in second trimester trisomy 21 pregnancies
To investigate the levels of placental growth factor (PlGF) in second trimester maternal serum in trisomy 21 cases and euploid controls – an unclear subject in the published literature.
Placenta growth factor levels in second‐trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia
To determine the levels of placenta growth factor (PlGF) in second‐trimester maternal serum samples from pregnancies affected with fetal Down syndrome and from those that developed preeclampsia and
First trimester maternal serum placental growth factor in trisomy 21 pregnancies
To examine placental growth factor (PlGF) levels in first trimester maternal serum in trisomy 21 pregnancies and to investigate the potential value of PlGF in a first trimester screening test.
Maternal serum placental growth factor at 11–13 weeks in chromosomally abnormal pregnancies
TLDR
To investigate the potential value of maternal serum placental growth factor (PlGF) in first‐trimester screening for trisomy 21 and other major chromosomal abnormalities, a small number of women were selected for screening.
Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests
TLDR
First trimester PlGF measurements improve the performance of antenatal screening for Down syndrome using the Combined, serum Integrated and Integrated tests.
Placenta growth factor elevation in the cord blood of premature neonates predicts poor pulmonary outcome.
TLDR
Measuring cord blood PlGF level at birth might be a biological marker for predicting the occurrence of BPD and allowing early therapeutic intervention.
Circulating angiogenic proteins in trisomy 13.
Use of Placental Growth Factor for Trisomy 21 Screening in Pregnancy: A Systematic Review
TLDR
Addition of PLGF to prenatal screening using serum analytes mildly improves trisomy 21 DRs as a function of false positive rates (FPRs), providing mean-weighted improvements in the DRs after accounting for PLGF levels.
Innovations in Down Syndrome Screening
TLDR
To improve the performance of the current DS screening programme, it would be useful to draw two separate blood samples and analyze several markers to increase the DR of first-trimester screening to almost 90%.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype
TLDR
The relation between maternal serum pregnancy associated plasma protein A (PAPP‐A) in the first trimester and the outcome of pregnancy by karyotype is assessed.
Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre‐eclampsia
Maternal serum inhibin A and free β human chorionic gonadotrophin (β‐hCG) were measured in 759 chromosomally normal, pregnant women at 10–14 weeks of gestation. There were nine who subsequently
Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre‐eclampsia
Objective To compare serum levels of angiogenic growth factors vascular endothelial growth factor (VEGF), placental growth factor (PIGF) and angiogenin in pre–eclamptic women and matched controls.
Placenta Growth Factor: Potential Role in Pregnancy
PROBLEM: In spite of the known requirement for adequate vascularity during placentation, little is known regarding the regulation of angiogenic growth factor production by trophoblast. Placenta
Maternal serum inhibin levels in second‐trimester down's syndrome pregnancies
TLDR
Although the inhibin levels were unrelated to those of alpha‐fetoprotein and unconjugated oestriol in the same samples, there was a statistically significant correlation with human chorionic gonadotropin, suggesting that inhibin would be of limited value in maternal serum screening for Down's syndrome.
Second‐trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome
TLDR
It is concluded that immunoreactive inhibin may be useful as a marker for fetal Down's syndrome.
Preeclampsia is associated with reduced serum levels of placenta growth factor.
Elevated Levels of Maternal Serum Inhibin Immunoreactivity in Second Trimester Pregnancies Affected by Down's Syndrome
TLDR
S In gestational trophoblastic disease such as hydatidiform mole, serum inhibin immunoreactivity has been shown to be significantly Elevated and levels fall to normal menstrual cycle levels after evacuation of the mole, and serum inhibIn immunore activity in such cases prior to evacuation are highly correlated with Total hCG concentrations.
Maternal Serum Total Activin a in Pregnancies Affected with Fetal Down's Syndrome
TLDR
Both total activin A and free activin are modestly raised in second trimester maternal serum samples from Down's syn­ drome pregnancies and neither activin marker appears to be as clinically useful as inhibin A in second Trimester prenatal serum screening.
...
...